dapagliflozin de astraZeneca Based on the detailed results of the study, significantly reduced the incidence of cardiovascular (CV) death or worsening heart failure (HF) in patients with slightly lower or preserved ejection fraction (EF) than placebo Phase III Deliver 3 Trial which have been presented at the 2022 Congress of the European Society of Cardiology, held in Barcelona, and published together The New England Journal of Medicine.
dapagliflozina CV reduced the overall outcome of death or HF by 18% (HR 0.82; 95% CI 0.73–0.92; P<0.001, 16.4%). dapagliflozin and 19.5% in the placebo group during a median follow-up of 2.3 years) all individual components contributed to the superiority of the primary endpoint.
The results were consistent across the major subgroups examined and extend the benefits of the drug to the full spectrum of HF patients, regardless of left ventricular ejection fraction (LVEF) status. Trial results also showed benefit Symptomatic on patient-reported outcome measures, as measured by the total symptom score of the Kansas City Cardiomyopathy Questionnaire (KCCQ).
L Dr Scott Solomon, Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital and principal investigator of the Phase III DELIVER trial explains that “these results are important for patients and clinical care, as they demonstrate that dapagliflozin effective regardless of ejection fraction and, therefore, can be used as a basic treatment in all patients
CI that meets the required requirements. Previous trials in HF-protected LVEFs have shown higher ejection fraction attenuation, but dapagliflozin results are consistent across the ejection fraction range.
These findings also reinforce the recommendation of the latest guidelines to start treatment as soon as possible, and May support wider use of SGLT2 inhibitors in clinical practice, “While HF patients with more than 40 percent LVEF are the most difficult to treat, there are few treatment options available,” explains Mene Pangalos, AstraZeneca’s executive vice president of biopharmaceuticals R&D. “We are proud to share DELIVER’s unprecedented results, which have advanced our understanding of the complexities of CI. These data add to our previous studies that demonstrate Cardiorenal Safety of Dapagliflozin in patients with type 2 diabetes,
Chronic kidney disease and HF”, he says.
deliver It was designed with broader inclusion criteria than previous trials for this type of patient and to include those with HFEF including hospitalized patients, recently hospitalized patients, or those with HF, for whom evidence-based treatment is limited. These findings add to the previously reported results of a trial of DAPA-HF, SGLT2i HF results that
demonstrated a reduction in cardiovascular mortality, providing further evidence to support the use of the drug as a therapy for patients with HF, regardless of ejection fraction. The primary endpoint was the time to first event of CV deathHospitalization for HF (HLC), or urgent visit for HF (HR 0.82 (95% CI 0.69 0.98). The safety and tolerability profile of dapagliflozin in the Phase III Delivered Trial was consistent with the well-established safety profile of the drug.
stop beating
HF is a long-term chronic disease that gets worse over time. It affects approximately 64 million people worldwide and is associated with significant morbidity and mortality., Chronic HF is the leading cause of hospitalization for people over the age of 65 and represents a significant clinical and economic burden. There are many types of CI,
often defined by the FEVI, A measure of the percentage of blood that is contracted each time, including HFREF (LVEF less than or equal to 40%), HFREF (LVEF 41–49%), and HFPEF (LVEF greater than or equal to 50%). , About half of all HF patients have rHFrEF or HFpEF, with few therapeutic options available.
